US 4737323A
· Martin et al.
· 1988
[cited by applicant]
US 5670631A
· Bayerl et al.
· 1997
[cited by applicant]
US 6296870B1
· Needham et al.
· 2001
[cited by applicant]
US 6868343B1
· Bayerl et al.
· 2005
[cited by applicant]
US 8734816B2
· Liu et al.
· 2014
[cited by applicant]
US 8758811B2
· Ho et al.
· 2014
[cited by applicant]
US 8992984B1
· Brinker et al.
· 2015
[cited by applicant]
US 9532949B2
· Zeinelden et al.
· 2017
[cited by applicant]
US 9579283B2
· Brinker et al.
· 2017
[cited by applicant]
US 20040005352A1
· Lopez et al.
· 2004
[cited by applicant]
US 20050249795A1
· Zhang et al.
· 2005
[cited by applicant]
US 20080175992A1
· Plieth et al.
· 2008
[cited by applicant]
US 20100284924A1
· Zink et al.
· 2010
[cited by applicant]
US 20100310465A1
· Zink et al.
· 2010
[cited by applicant]
US 20110104073A1
· Zeng et al.
· 2011
[cited by applicant]
US 20120021034A1
· Zink et al.
· 2012
[cited by applicant]
US 20120207795A1
· Zink et al.
· 2012
[cited by applicant]
US 20140138278A1
· Kennedy
· 2014
[cited by applicant]
US 20140301951A1
· Liu et al.
· 2014
[cited by applicant]
US 20150272885A1
· Ashley et al.
· 2015
[cited by applicant]
US 20170095418A1
· Zink et al.
· 2017
[cited by applicant]
AU 2017206077B2
· 2021
[cited by applicant]
EP 2964201A1
· 2016
[cited by applicant]
WO WO2006015757A1
· 2006
[cited by applicant]
WO WO2006032136A1
· 2006
[cited by applicant]
WO WO2010078569A2
· 2010
[cited by applicant]
WO WO2012009448A2
· 2012
[cited by applicant]
WO WO2012149376A2
· 2012
[cited by applicant]
WO WO2013012891A1
· 2013
[cited by applicant]
WO WO2014138278A1
· 2014
[cited by applicant]
WO WO2017013250A1
· 2017
[cited by applicant]
WO WO2017120537A1
· 2017
[cited by applicant]
WO WO2019133884A1
· 2019
[cited by applicant]
US Office Action (Restriction Requirement), dated Feb. 3, 2017, issued in U.S. Appl. No. 14/772,740.
[cited by applicant]
US Office Action dated Jun. 2, 2017, issued in U.S. Appl. No. 14/772,740.
[cited by applicant]
US Final Office Action dated Feb. 20, 2018, issued in U.S. Appl. No. 14/772,740.
[cited by applicant]
US Advisory Action dated Jun. 1, 2018, issued in U.S. Appl. No. 14/772,740.
[cited by applicant]
US Office Action dated Aug. 7, 2018, issued in U.S. Appl. No. 14/772,740.
[cited by applicant]
US Final Office Action dated Apr. 1, 2019, issued in U.S. Appl. No. 14/772,740.
[cited by applicant]
US Office Action dated Nov. 27, 2019, issued in U.S. Appl. No. 14/772,740.
[cited by applicant]
US Office Action dated Jan. 31, 2018 issued in U.S. Appl. No. 15/798,287.
[cited by applicant]
US Office Action dated May 29, 2018 issued in U.S. Appl. No. 15/798,287.
[cited by applicant]
US Notice of Allowance dated Jul. 19, 2018 issued in U.S. Appl. No. 15/798,287.
[cited by applicant]
US Office Action dated Sep. 4, 2019 issued in U.S. Appl. No. 16/164,030.
[cited by applicant]
US Miscellaneous Communication dated Apr. 22, 2020 issued in U.S. Appl. No. 16/164,030.
[cited by applicant]
US Examiner Initiated Interview Summary dated Apr. 23, 2020 issued in U.S. Appl. No. 16/164,030.
[cited by applicant]
U.S. Appl. No. 14/253,030 Office Action dated Dec. 9, 2016.
[cited by applicant]
U.S. Appl. No. 14/253,030 Response as filed on May 9, 2017.
[cited by applicant]
PCT International Search Report and Written Opinion dated Jun. 24, 2014 issued in PCT/US2014/020857.
[cited by applicant]
PCT International Report on Patentability and Written Opinion dated Sep. 17, 2015 issued in PCT/US2014/020857.
[cited by applicant]
European Extended Search Report dated Jul. 27, 2016 issued in Application No. EP 14 760 467.2.
[cited by applicant]
European Office Action dated Aug. 23, 2018 issued in Application No. EP 14 760 467.2.
[cited by applicant]
PCT International Search Report and Written Opinion dated Apr. 18, 2017 issued in PCT/US2017/012625.
[cited by applicant]
PCT International Preliminary Report on Patentability and Written Opinion dated Jul. 10, 2018 issued in PCT/US2017/012625.
[cited by applicant]
European Extended Search Report dated Aug. 7, 2019 issued in Application No. EP 17736481.7.
[cited by applicant]
PCT International Search Report and Written Opinion dated Mar. 27, 2019 issued in PCT/US18/67970.
[cited by applicant]
Abigerges et al. (1995) “Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.”
[cited by applicant]
Al Shamsi et al. (2010) “Biocompatibility of calcined mesoporous silica particles with cellular bioenergetics in murine tissues.”
[cited by applicant]
Angelos et al. (2007) “Mesostructured silica supports for functional materials and molecular machines.”
[cited by applicant]
Argyo, et al. (2013) “Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery.”
[cited by applicant]
Arruebo et al. (2006) “Development of Magnetic Nanostructured Silica-Based Materials as Potential Vectors for Drug-Delivery Applications.”
[cited by applicant]
Arruebo et al. (Published Jul. 18, 2006) “Sustained release of doxorubicin from zeolite-magnetite nanocomposited prepared by mechanical activation.”
[cited by applicant]
Aryal, et al. (2011) “Polymeric Nanoparticles with Precise Ratiometric Control over Drug Loading for Combination Therapy.”
[cited by applicant]
Ashley et al. (2011) “The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers.”
[cited by applicant]
Ashley et al. (2012) “Delivery of Small Interfering RNA by Peptide-Targeted Mesoporous Silica Nanoparticle-Supported Lipid Bilayers.”
[cited by applicant]
Awasthi et al. (2013) “Comparative Benefits of Nab-Paclitaxel over Gemcitabine or Polysor-bate-Based Docetaxel in Experimental Pancreatic Cancer.”
[cited by applicant]
Bagwe et al. (Apr. 25, 2006) “Surface Modification of Silica Nanoparticles to Reduce Aggregation and Nonspecific Binding.”
[cited by applicant]
Baker et al. (2008) “Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin.”
[cited by applicant]
Barbe et al. (2004) “Silica particles: A novel drug-delivery system.”
[cited by applicant]
Bardelle (1993) “Membrane binding kinetics of factor VIII indicate a complex binding process.”
[cited by applicant]
Bayerl, et al. (1990) “Physical Properties of Single Phospholipid Bilayers Adsorbed to Micro Glass Beads. A New Vesicular Model System Studied by 2H-Nuclear Magnetic Resonance.”
[cited by applicant]
Bourzac, K. (2012) “Nanotechnology: Carrying Drugs.”
[cited by applicant]
Brigger et al. (2002) “Nanoparticles in cancer therapy and diagnosis.”
[cited by applicant]
Brumm et al. (1996) “The effect of increasing membrane curvature on the phase transition and mixing behavior of a dimyristoyl-sn-glycero-3-phosphatidylcholine/distearoyl-sn-glycero-3-phosphatidylcholine lipid mixture as…
[cited by applicant]
Buck et al. (2004) “Engineering Lipobeads: Properties of the Hydrogel Core and the Lipid Bilayer Shell”
[cited by applicant]
Buranda et al. (2003) “Biomimetic Molecular Assemblies on Glass and Mesoporous Silica Microbeads for Biotechnology”
[cited by applicant]
Carmona-Ribeiro (2003) “Bilayer-forming synthetic lipids: drugs or carriers?”
[cited by applicant]
Cauda et al. (2010) “Colchicine-Loaded Lipid Bilayer-Coated 50 nm Mesoporous Nanoparticles Efficiently Induce Microtubule Depolymerization upon Cell Uptake”
[cited by applicant]
Celano et al. (2004) “Cytotoxic effects of Gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells,”
[cited by applicant]
“CHEBI:53581—cetyttrimethylammonium chloride”, Retrieved from the Internet: URL https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:53581, Sep. 11, 2013 (Sep. 11, 2013), Section “Synonyms”.
[cited by applicant]
Chemburu et al. (2010) “Biomimetic Silica Microspheres in Biosensing”
[cited by applicant]
Chen et al. (2009) “Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug Resistant Cancer Cells.”
[cited by applicant]
Chen, et al. (2014) “Antitumor efficacy of irinotecan-loaded galactosyl modified lipid bilayer-coated mesoporous silica nanoparticles against hepatocellular carcinoma cells.”
[cited by applicant]
Cho et al. (2008) “Therapeutic nanoparticles for drug delivery in cancer.”
[cited by applicant]
Chou et al. (2003) “Effect of Composition on the stability of liposomal irinotecan prepared by a pH gradient method.”
[cited by applicant]
Cosco et al. (2009) “In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer”
[cited by applicant]
Davis et al. (2008) “Nanoparticle therapeutics: an emerging treatment modality for cancer.”
[cited by applicant]
Davis, M. E., (2009) “The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic.”
[cited by applicant]
Dengler et al. (2013) “Mesoporous Silica-Supported Lipid Bilayers (Protocells) for DNA Cargo Delivery to the Spinal Cord.”
[cited by applicant]
Dolainsky et al. (1993) “Transverse relaxation in supported and nonsupported phospholipid model membranes and the influence of ultraslow motions: A 31P-NMR study”
[cited by applicant]
Drummond et al. (2006) “Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy.”
[cited by applicant]
Duncan et al. (2005) “Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer.”
[cited by applicant]
Eschwege et al. (1996) “Detection of bilayer phospholipid-binding antibodies using flow cytometry”
[cited by applicant]
Federico et al. (2012) “Gemcitabine-Loaded Liposomes: Rationale, Potentialities and Future Perspectives.”
[cited by applicant]
Ferrari, M. (2005) “Cancer Nanotechnology: Opportunities and Challenges.”
[cited by applicant]
Frese et al. (2012) “Nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer.”
[cited by applicant]
Fritze et al. (2006) “Remote loading of doxorubicin into liposomes driven by transmembrane phosphate gradient,”
[cited by applicant]
Fuchs et al. (2006) “Irinotecan in the treatment of colorectal cancer.”
[cited by applicant]
Gahlyan et al. (2014) “Oral Controlled Release Drug Delivery System—A Review”
[cited by applicant]
Gilbert et al. (1992) “Specificity of phosphatidylserine-containing membrane binding sites for factor VIII. Studies with model membranes supported by glass microspheres (lipospheres).”
[cited by applicant]
Gorelikov et al. (2008) “Single-step coating of mesoporous silica on cetyltrimethyl ammonium bromide-capped nanoparticles.”
[cited by applicant]
Grün et al. (1997) “The Synthesis of Micrometer- and Submicrometer-Size Spheres of Ordered Mesoporous Oxide MCM-41.”
[cited by applicant]
Guiotto et al. (2004) “Synthesis, Characterization, and Preliminary in Vivo Tests of New Poly(ethylene glycol) Conjugates of the Antitumor Agent 10-Amino-7-ethylcamptothecin.”
[cited by applicant]
Haran et al. (1993) “Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.”
[cited by applicant]
He et al. (2011) “In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation.”
[cited by applicant]
Hetzer et al. (1998) “Asymmetric Molecular Friction in Supported Phospholipid Bilayers Revealed by NMR Measurements of Lipid Diffusion”
[cited by applicant]
Jabr-Milane et al. (2008) “Multi-functional nanocarriers to overcome tumor drug resistance.”
[cited by applicant]
Jin et al. (1996) “Lipobeads: a hydrogen anchored lipid vesicle system”
[cited by applicant]
Junglas et al. (2003) “Molecular Order Parameter Profiles and Diffusion Coefficients of Cationic Lipid Bilayers on a Solid Support”
[cited by applicant]
Kasbauer et al. (1999) “Effect of cationic lipids in the formation of asymmetries in supported bilayers.”
[cited by applicant]
Katiyar et al. (2006) “Synthesis of ordered large pore SBA-15 spherical particles for adsorption of biomolecules.”
[cited by applicant]
Kiser et al. (1998) “A synthetic mimic of the secretory granule for drug delivery”
[cited by applicant]
Kiser et al. (2000) “Lipid-coated microgels for the triggered release of doxorubicin” J. Control Release, 68: 9-22.
[cited by applicant]
Kneuer et al. (2000) “A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro.”
[cited by applicant]
Kochy & Bayerl (1993) “Lateral diffusion coefficients of phospholipids in spherical bilayers on a solid support measured by resonance relaxation”
[cited by applicant]
Lammers et al. (2010) “Nanomedicine Formulations for Combination Therapies.”
[cited by applicant]
Lee et al. (2008) “Synthesis and characterization of positive-charge functionalized mesoporous silica nanoparticles for oral drug delivery of an anti-inflammatory drug.”
[cited by applicant]
Li et al. (2012) “Mesoporous silica nanoparticles in biomedical applications.”
[cited by applicant]
Li et al. (2013) “Preliminary study on pH-sensitive lipid bilayer-coated mesoporous silica nanoparticles as a novel drug carrier for antitumor drug.”
[cited by applicant]
Li et al. (2015) “Multiple Layer-by-Layer Lipid-Polymer Hybrid Nanoparticles for Improved FOLFIRINOX Chemotherapy in Pancreatic Tumor Models.”
[cited by applicant]
Lin et al. (2009) “Synthesis and Characterization of Biocompatible and Size-Tunable Multifunctional Porous Silica Nanoparticles.”
[cited by applicant]
Linseisen et al. (1996) “2H-NMR and DSC study of DPPC-DODAB mixtures”
[cited by applicant]
Linseisen et al. (1997) “Differences in the Physical Properties of Lipid Monolayers and Bilayers on a Spherical Solid Support.”
[cited by applicant]
Liong et al. (2008) “Multifunctional inorganic nanoparticles for imaging, targeting and drug delivery.”
[cited by applicant]
Liong et al. (2009) “Mesostructured Multifunctional Nanoparticles for Imaging and Drug Delivery.”
[cited by applicant]
Liu et al. (2009) “Electrostatically Mediated Liposome Fusion and Lipid Exchange with a Nanoparticle-Supported Bilayer for Control of Surface Charge, Drug Containment, and Delivery.”
[cited by applicant]
Liu et al. (2009) “Porous Nanoparticle Supported Lipid Bilayers (Protocells) as Delivery Vehicles,”
[cited by applicant]
Liu et al. (2012) “Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells”
[cited by applicant]
Liu et al. (2016) “Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer.”
[cited by applicant]
Liu et al. (2016) “Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer.”
[cited by applicant]
Loidl-Stahlhofen et al. (2001) “Multilamellar liposomes and solid-supported lipid membranes (TRANSIL): screening of lipid-water partitioning toward a high-throughput scale”
[cited by applicant]
Loidl-Stahlhofen et al. (2001) “Solid-Supported Biomolecules on Modified Silica Surfaces—A Tool for Fast Physicochemical Characterization and High-Throughput Screening”
[cited by applicant]
Loidl-Stahlhofen et al. (2001) “Solid-supported lipid membranes as a tool for determination of membrane affinity: High-throughput screening of a physicochemical parameter.”
[cited by applicant]
Loidl-Stahlhofen et al. (1996) “The thermodynamic control of protein binding to lipid bilayers for protein chromatography”
[cited by applicant]
Lu et al. (2007) “Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs.”
[cited by applicant]
Ma et al. (2013) “Nanoparticles for Combination Drug Therapy.”
[cited by applicant]
Mackowiak et al. (2013) “Targeted Drug Delivery in Cancer Cells with Red-Light Photoactivated Mesoporous Silica Nanoparticles.”
[cited by applicant]
Mai et al. (2013) “Mesoporous Silica Nanoparticles: A Multifunctional Nano Therapeutic System.”
[cited by applicant]
Mayer et al. (2007) “Optimizing Combination Chemotherapy by Controlling Drug Ratios.”
[cited by applicant]
Meng et al. (2006) “A Family of Highly Ordered Mesoporous Polymer Resin and Carbon Structures from Organic-Organic Self-Assembly.”
[cited by applicant]
Meng et al. (2010) “Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves.”
[cited by applicant]
Meng et al. (2010) “Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line,”
[cited by applicant]
Meng et al. (2010) “Potent Angiogenesis Inhibition by the Particulate Form of Fullerene Derivatives.”
[cited by applicant]
Meng et al. (2011) “Aspect Ratio Determines the Quantity of Mesoporous Silica Nanoparticle Uptake by a Small GTPase-Dependent Macropinocytosis Mechanism,”
[cited by applicant]
Meng et al. (2011) “Use of Size and a Copolymer Design Feature To Improve the Biodistribution and the Enhanced Permeability and Retention Effect of Doxorubicin Loaded Mesoporous Silica Nanoparticles in a Murine Xenograf…
[cited by applicant]
Meng et al. (2012) “Development of Pharmaceutically Adapted Mesoporous Silica Nanoparticles Platform.”
[cited by applicant]
Meng et al. (2013) “Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nano-particles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo.”
[cited by applicant]
Meng et al. (2013) “Two-Wave Nanotherapy to Target the Stroma and Optimize Gemcitabine Delivery to a Human Pancreatic Cancer Model in Mice,”
[cited by applicant]
Meng et al. (2015) “Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice”
[cited by applicant]
Messerer et al. (2004) “Liposomal Irinotecan: Formulation Development and Therapeutic Assessment in Murine Xenograft Models of Colorectal Cancer.”
[cited by applicant]
Miao et al. (2014) “Nanoparticles with Precise Ratiometric Co-loading and Co-delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.”
[cited by applicant]
Moore et al. (2007) “Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.”
[cited by applicant]
Mornet, et al. (2005) “The Formation of Supported Lipid Bilayers on Silica Nanoparticles Revealed by Cryoelectron Microscopy.”
[cited by applicant]
Moura & Carmona-Ribeiro (2003) “Cationic Bilayer Fragments on Silica at Low Ionic Strength: Competitive Adsorption and Colloid Stability”
[cited by applicant]
Moura & Carmona-Ribeiro (2005) “Biomimetic Particles: Optimization of Phospholipid Bilayer Coverage on Silica and Colloid Stabilization”
[cited by applicant]
Naumann et al. (1992) “Phase transition behavior of single phosphatidylcholine bilayers on a solid spherical support studied by DSC, NMR and FT-IR”
[cited by applicant]
Ng et al. (2001) “One-Step Synthesis of a Fluorescent Phospholipid-Hydrogel Conjugate for Driving Self-Assembly of Supported Lipid Membranes”
[cited by applicant]
Ng et al. (2004) “Properties of a Self-Assembled Phospholipid Membrane Supported on Lipobeads”
[cited by applicant]
Nordlund et al. (2009) “Formation of supported lipid bilayers on silica particles studied using flow cytometry.”
[cited by applicant]
Obringer et al.(1995) Antiphospholipid antibody binding to bilayer-coated glass microspheres
[cited by applicant]
Onishi et al. (2003) “Antitumor Properties of Irinotecan-Containing Nanoparticles Prepared Using Poly(DL-lactic acid) and Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol).”
[cited by applicant]
Onivyde (irinotecan liposome injection)—Highlights of Prescribing Information—Reference ID: 3836766; 18 pages [accessed Oct. 23, 2015]. Retrieved from the Internet, URL: https://www.accessdata.fda.gov/drugsatfda_docs/la…
[cited by applicant]
Park et al. (2004) “Characterization of radioligand binding to a transmembrane receptor reconstituted into Lipobeads”
[cited by applicant]
Pasqua et al. (Published online Feb. 3, 2007) “Preparation of bifunctional hybrid mesoporous silica potentially useful for drug targeting.”
[cited by applicant]
Patil et al. (2010) “Use of nanoparticle mediated gene silencing and drug delivery to overcome tumor drug resistance.” Biomaterials 31:358-365.
[cited by applicant]
Pearse et al. (1987) “Structure and assembly of coated vesicles.”
[cited by applicant]
Peer, et al. (2007) “Nanocarriers as an Emerging Platform for Cancer Therapy.”
[cited by applicant]
Piyasena et al. (2008) “Biosensors based on release of compounds upon disruption of lipid bilayers supported on porous microspheres.”
[cited by applicant]
Ramsay et al. (2008) “A novel liposomal irinotecan formulation with significant anti-tumour activity: Use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.”
[cited by applicant]
Rapuano & Carmona-Ribeiro (1997) “Physical Adsorption of Bilayer Membranes on Silica”
[cited by applicant]
Rapuano & Carmona-Ribeiro (2000) “Supported Bilayers On Silica”
[cited by applicant]
Reinl & Bayerl (1993) “Interaction of myelin basic protein with single bilayers on a solid support: an NMR, DSC and polarized infrared ATR study”
[cited by applicant]
Reinl & Bayerl (1994) “Lipid Transfer between Small Unilamellar Vesicles and Single Bilayers on a Solid Support: Self-Assembly of Supported Bilayers with Asymmetric Lipid Distribution”
[cited by applicant]
Roggers et al. (2012) “Chemically Reducible Lipid Bilayer Coated Mesoporous Silica Nano-particles Demonstrating Controlled Release and HeLa and Normal Mouse Liver Cell Biocompatibility and Cellular Internalization.”
[cited by applicant]
Roiter et al. (2008) “Interaction of Nanoparticles with Liquid Membrane.”
[cited by applicant]
Saad et al. (2008) “Co-delivery of siRNA and an anticancer drug for treatment of multi-drug resistant cancer.”
[cited by applicant]
Sachae et al. (2017) “Surfactant-Templating of Zeolites: From Design to Application”
[cited by applicant]
Sackmann, E. (1996) “Supported Membranes: Scientific and Prac-tical Applications.”
[cited by applicant]
Sadzuka et al. (1998) “Effect of liposomalization on the antitumor activity, side-effects and tissue distribution of CPT-11.”
[cited by applicant]
Santos et al. (2009) “The Power of Ultrasound”,
[cited by applicant]
Schmitt et al. (2001) “Polymer Cushions in Supported Phospholipid Bilayers Reduce Significantly the Frictional Drag between Bilayer and Solid Surface”
[cited by applicant]
Schmitz et al. (1999) “Interactions of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS)-Related Protein with a Novel Solid-Supported Lipid Membrane System (TRANSIL)”
[cited by applicant]
Schuhmacher et al. (2004) “High-throughput determination of the free fraction of drugs strongly bound to plasma proteins.”
[cited by applicant]
Sharma et al. (2004) “Bacteriorhodopsin conjugates as anchors for supported membranes.”
[cited by applicant]
Shidhaye et al. (2008) “Nanogel Engineered Polymeric Micelles for Drug Delivery.”
[cited by applicant]
Singh et al. (2008) “Nanoengineering artificial lipid envelopes around adenovirus by self-assembly.”
[cited by applicant]
Slowing et al. (2008) “Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers.”
[cited by applicant]
Sommerwerk et al. (2011) “Lipid Coated Chitosan Micro-particles as Protein Carriers.”
[cited by applicant]
Sugahara et al. (2010) “Coadministration of a tumor-penetrating peptiden enhances the efficacy fo cancer drugs.”
[cited by applicant]
Szakacs et al. (2006) “Targeting multidrug resistance in cancer.”
[cited by applicant]
Tamanoi “Nanodelivery: Towards controlled release of anti-cancer drugs.” Oral Presentation on Dec. 6, 2006 (see NanoBio-Tokyo 2006 Program), 7 pages. Abstract provided in Proceedings of UT Symposium on NanoBio Integrati…
[cited by applicant]
Tang et al. (2012) “Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery.”
[cited by applicant]
Tardi et al. (2009) “In Vivo Maintenance of Synergistic Cytarabine: Daunorubicin Ratios Greatly Enhances Therapeutic Efficacy.”
[cited by applicant]
Tarn et al. (2013) “Mesoporous Silica Nanoparticle Nanocarriers: Biofunctionality and Biocompatibility.”
[cited by applicant]
Thorolfsson et al. (2002) “The binding of tyrosine hydroxylase to negatively charged lipid bilayers involves the N-terminal region of the enzyme.”
[cited by applicant]
Torney et al. (2007) “Mesoporous silica nanoparticles deliver DNA and chemicals into plants.”
[cited by applicant]
Troutier & Lada Viere (2007) “An overview of lipid membrane supported by colloidal particles.”
[cited by applicant]
Valencia et al. (2013) “Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles.”
[cited by applicant]
Van Schooneveld et al. (2008) “Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation.”
[cited by applicant]
Van Vlerken et al. (2007) “Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.”
[cited by applicant]
Von Hoff et al. (2011) “Gemcitabine Plus Nab-Paclitaxel Is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/II Trial.”
[cited by applicant]
Von Hoff et al. (2013) “Increased Survival in Pancreatic Cancer with Nab-Paclitaxel Plus Gemcitabine.”
[cited by applicant]
Wu et al. (2007) “Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.”
[cited by applicant]
Xia et al. (2009) “Polyethyleneimine Coating Enhances the Cellular Uptake of Mesoporous Silica Nanoparticles and Allows Safe Delivery of siRNA and DNA Constructs.”
[cited by applicant]
Xu et al. (2013) “Biodistribution and Pharmacokinetics of EGFR-Targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-Bearing Mice.”
[cited by applicant]
Yang et al. (2010) “Lipid Coated Mesoporous Silica Nanoparticles as Photosensitive Drug Carriers.”
[cited by applicant]
Yezhelyev et al. (2008) “Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging.”
[cited by applicant]
Zhang et al. (2011) “Synergistic Antitumor Activity of Gemcitabine and ABT-737 in Vitro and in Vivo through Disrupting the Interaction of USP9X and Mcl-1.”
[cited by applicant]
Zhang et al. (2013) “Facile Large-Scale Synthesis of Monodisperse Mesoporous Silica Nanospheres with Tunable Pore Structure”
[cited by applicant]
Zhang et al. (2014) “Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.”
[cited by applicant]
Zhu et al. (2004) “Poly(L-lysine)-modified silican nanoparticles for the delivery of anitsense oligonucleotides.”
[cited by applicant]
Zucker et al. (2009) “Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties.”
[cited by applicant]
US Notice of Allowance dated Jun. 22, 2020, issued in U.S. Appl. No. 14/772,740.
[cited by applicant]
US Notice of Allowance dated May 6, 2020, issued in U.S. Appl. No. 16/164,030.
[cited by applicant]
European 2nd Office Action dated May 26, 2020 issued in Application No. EP 14 760 467.2.
[cited by applicant]
PCT International Preliminary Report on Patentability and Written Opinion dated Jul. 7, 2020 issued in PCT/US18/67970.
[cited by applicant]
Chen, et al. (2014) “Antitumor efficacy of irinotecan-loaded galactosyl modified lipid bilayer-coated mesoporous silica nanoparticles against hepatocellular carcinoma cells.”
[cited by applicant]
Li et al. (2013) “Preliminary study on pH-sensitive lipid bilayer-coated mesoporous silica nanoparticles as a novel drug carrier for antitumor drug.”
[cited by applicant]
U.S. Appl. No. 16/947,539, filed Aug. 5, 2020, Nel et al.
[cited by applicant]
U.S. Appl. No. 16/948,498, filed Sep. 21, 2020, Nel et al.
[cited by applicant]
US Office Action dated Sep. 9, 2020, issued in U.S. Appl. No. 16/947,539.
[cited by applicant]
US Notice of Allowance dated Apr. 21, 2021 issued in U.S. Appl. No. 16/947,539.
[cited by applicant]
Australian Office Action dated Dec. 17, 2020 issued in AU 2017206077.
[cited by applicant]
Chinese Office Action dated Aug. 14, 2020 issued in CN 201780010248.8.
[cited by applicant]
Chinese 2nd Office Action dated May 17, 2021 issued in CN 201780010248.8.
[cited by applicant]
Japanese Office Action dated Oct. 5, 2020 issued in JP 2018-535362.
[cited by applicant]
Korean Office Action dated May 18, 2021 issued in KR 10-2018-7022622.
[cited by applicant]
CN Office Action dated Jan. 30, 2022, in Application No. CN201780010248.8 with English translation.
[cited by applicant]
Co-pending U.S. Appl. No. 17/384,214, filed Jul. 23, 2021.
[cited by applicant]
Daqing Li., et al., “Critical Micelle Concentrations of Cetyltrimethylammonium Chloride and Their Influence on the Periodic Structure of Mesoporous Silica”, Colloid Journal of The Russian Academy of Science—Kolloidnyyie…
[cited by applicant]
EP Partial Supplemental Search Report dated Nov. 11, 2021 in EP Application No. 18897783.9.
[cited by applicant]
European 3rd Office Action dated Sep. 2, 2021 issued in Application No. EP 14 760 467.2.
[cited by applicant]
Extended European Search Report dated Mar. 15, 2022, in Application No. 18897783.9.
[cited by applicant]
Japanese 2nd Office Action dated Aug. 2, 2021 issued in JP 2018-535362.
[cited by applicant]
AU Office action dated May 22, 2023, in AU Application No. AU2022200881.
[cited by applicant]
CA Office Action dated Oct. 24, 2023, in Application No. CA3010711.
[cited by applicant]
EP Extended European Search Report dated Jul. 11, 2023, in Application No. 23158990.4.
[cited by applicant]
JP Office Action dated Apr. 17, 2023 in Application No. JP2022-72344 with English translation.
[cited by applicant]
JP Office Action dated Oct. 16, 2023 in Application No. JP2022-72344 with English translation.
[cited by applicant]
KR Office Action dated Mar. 22, 2023 in Application No. KR10-2022-7019372 with English translation.
[cited by applicant]
KR Office Action dated Sep. 25, 2023 in Application No. KR10-2022-7019372 with English translation.
[cited by applicant]
U.S. Non-Final Office Action dated Aug. 22, 2023, in U.S. Appl. No. 16/948,498.
[cited by applicant]
U.S. Non-Final Office Action dated Jul. 24, 2023, in U.S. Appl. No. 17/384,214.
[cited by applicant]
U.S. Notice of Allowance dated Nov. 17, 2023 in U.S. Appl. No. 16/948,498.
[cited by applicant]